Cargando…

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

BACKGROUND: Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refoldi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fransson, Åsa, Glaessgen, Daria, Alfredsson, Jessica, Wiman, Klas G., Bajalica-Lagercrantz, Svetlana, Mohell, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868029/ https://www.ncbi.nlm.nih.gov/pubmed/27179933 http://dx.doi.org/10.1186/s13048-016-0239-6

Ejemplares similares

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
por: Frebourg, Thierry, et al.
Publicado: (2020)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Germline TP53 Testing in Breast Cancers: Why, When and How?
por: Evans, D. Gareth, et al.
Publicado: (2020)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
por: Omran, Meis, et al.
Publicado: (2020)

Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
por: Altena, Renske, et al.
Publicado: (2022)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer
por: Liu, Yaxuan, et al.
Publicado: (2021)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Expression of the p53 Target Wig-1 Is Associated with HPV Status and Patient Survival in Cervical Carcinoma
por: Xu, Li-Di, et al.
Publicado: (2014)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

Whole-Body MRI Surveillance—Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53)
por: Omran, Meis, et al.
Publicado: (2022)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
por: Müller, Michael, et al.
Publicado: (2021)

Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c(+) Expression in Tumor
por: Magalhaes, Isabelle, et al.
Publicado: (2020)

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
por: Zhou, Xingchen, et al.
Publicado: (2015)

Reply to Kratz et al.
por: Frebourg, Thierry, et al.
Publicado: (2020)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nkeece84igcogupe7dq5unh12r